2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

2:30PM-4:00PM: Abstract Number: 2009

CC-Chemokine Receptor 7 (CCR7) Deficiency Reduces Early Structural and Functional Features of Disease in a Murine Model of Osteoarthritis

Biology and Pathology of Bone and Joint: Ostearthritis Pathogenesis

2:30PM-4:00PM: Abstract Number: 2043

Cell-Bound Complement Activation Products Have High Sensitivity and Specificity in Childhood-Onset Systemic Lupus Erythematosus and Juvenile Idiopathic Arthritis

Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2032

Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis

Infection-related Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2005

Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients

Antiphospholipid Syndrome: Recent findings

2:30PM-4:00PM: Abstract Number: 2035

Clinical Characteristics and Outcomes of Polyarticular Septic Arthritis

Infection-related Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2033

Clinical Manifestations Associated with Peripheral Joint Involvement in Patients with Acute Chikungunya Virus Infection

Infection-related Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2028

Contribution of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia Rheumatica: A Controlled Study

Imaging of Rheumatic Diseases II: MRI, PET and CT

2:30PM-4:00PM: Abstract Number: 2045

Cross-Validation of the Pediatric Automated Neuropsychological Assessment Metrics-Cognitive Performance Scores in the Screening of Neurocognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2067

De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Biomarkers

2:30PM-4:00PM: Abstract Number: 2014

Deficiency of IL-27 Exacerbate Sjögren’s Syndrome through Inhibiting Differentiation of Type 1 Regulatory T Cells

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

2:30PM-4:00PM: Abstract Number: 2027

Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout

Imaging of Rheumatic Diseases II: MRI, PET and CT

2:30PM-4:00PM: Abstract Number: 2076

Development of Lupus Nephritis: Preclinical Evaluation of Patients Who Subsequently Develop Systemic Lupus Erythematosus Demonstrate Elevation of Select Soluble Mediators Prior to and at Disease Classification in Patients with Nephritis

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Modulators of Disease

2:30PM-4:00PM: Abstract Number: 2007

Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis

Biology and Pathology of Bone and Joint: Ostearthritis Pathogenesis

2:30PM-4:00PM: Abstract Number: 2011

Disruption of the Molecular Clock in Mesenchymal Cells Causes an Osteoarthritis-like Disease in Mice

Biology and Pathology of Bone and Joint: Ostearthritis Pathogenesis

2:30PM-4:00PM: Abstract Number: 2017

DNA Methylation Governs the Ability of Apoptotic Cells to Suppress Inflammatory Arthritis Via Reciprocal Regulation of IL-6 and TGF-Beta

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].